255 related articles for article (PubMed ID: 24480288)
1. [Prevention of hepatic encephalopathy].
Morillas RM; Sala M; Planas R
Med Clin (Barc); 2014 Jun; 142(11):512-4. PubMed ID: 24480288
[TBL] [Abstract][Full Text] [Related]
2. Lactitol in prevention of recurrent episodes of hepatic encephalopathy in cirrhotic patients with portal-systemic shunt.
Riggio O; Balducci G; Ariosto F; Merli M; Pieche U; Pinto G; Tremiterra S; Ziparo V; Capocaccia L
Dig Dis Sci; 1989 Jun; 34(6):823-9. PubMed ID: 2656134
[TBL] [Abstract][Full Text] [Related]
3. [Role of rifaximin in the treatment of hepatic encephalopathy].
Sanchez-Delgado J; Miquel M
Gastroenterol Hepatol; 2016 Apr; 39(4):282-92. PubMed ID: 26545947
[TBL] [Abstract][Full Text] [Related]
4. Rifaximin treatment in hepatic encephalopathy.
Sharma P; Sharma BC
N Engl J Med; 2010 Jun; 362(25):2423-4; author reply 2424-5. PubMed ID: 20578274
[No Abstract] [Full Text] [Related]
5. Update on management of patients with overt hepatic encephalopathy.
Chacko KR; Sigal SH
Hosp Pract (1995); 2013 Aug; 41(3):48-59. PubMed ID: 23948621
[TBL] [Abstract][Full Text] [Related]
6. Lactitol in the treatment of chronic hepatic encephalopathy--a randomized cross-over comparison with lactulose.
Riggio O; Balducci G; Ariosto F; Merli M; Tremiterra S; Ziparo V; Capocaccia L
Hepatogastroenterology; 1990 Oct; 37(5):524-7. PubMed ID: 2253931
[TBL] [Abstract][Full Text] [Related]
7. Disaccharides in the treatment of hepatic encephalopathy.
Sharma P; Sharma BC
Metab Brain Dis; 2013 Jun; 28(2):313-20. PubMed ID: 23456517
[TBL] [Abstract][Full Text] [Related]
8. Hepatic encephalopathy: pathophysiology and emerging therapies.
Sundaram V; Shaikh OS
Med Clin North Am; 2009 Jul; 93(4):819-36, vii. PubMed ID: 19577116
[TBL] [Abstract][Full Text] [Related]
9. [Prevention and treatment of hepatic encephalopathy].
Sivolap YP
Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(10):144-147. PubMed ID: 29171503
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy for the treatment and prevention of hepatic encephalopathy.
Mohammad RA; Regal RE; Alaniz C
Ann Pharmacother; 2012 Nov; 46(11):1559-63. PubMed ID: 23092866
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study.
Riggio O; Masini A; Efrati C; Nicolao F; Angeloni S; Salvatori FM; Bezzi M; Attili AF; Merli M
J Hepatol; 2005 May; 42(5):674-9. PubMed ID: 15826716
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of rifaximin versus lactulose for reducing the recurrence of overt hepatic encephalopathy and hopitalizations in cirrhosis.
Irimia R; Trifan A
Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):1021-7. PubMed ID: 23700882
[TBL] [Abstract][Full Text] [Related]
13. RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.
Schulz C; Schütte K; Kropf S; Schmitt FC; Vasapolli R; Kliegis LM; Riegger A; Malfertheiner P
Trials; 2016 Feb; 17(1):111. PubMed ID: 26926775
[TBL] [Abstract][Full Text] [Related]
14. Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence?
Gluud LL; Dam G; Borre M; Les I; Cordoba J; Marchesini G; Aagaard NK; Vilstrup H
Metab Brain Dis; 2013 Jun; 28(2):221-5. PubMed ID: 23275147
[TBL] [Abstract][Full Text] [Related]
15. Primary Prophylaxis to Prevent the Development of Hepatic Encephalopathy in Cirrhotic Patients with Acute Variceal Bleeding.
Higuera-de-la-Tijera F; Servín-Caamaño AI; Salas-Gordillo F; Pérez-Hernández JL; Abdo-Francis JM; Camacho-Aguilera J; Alla SN; Jiménez-Ponce F
Can J Gastroenterol Hepatol; 2018; 2018():3015891. PubMed ID: 30079329
[TBL] [Abstract][Full Text] [Related]
16. Optimal treatment of hepatic encephalopathy.
Waghray A; Waghray N; Kanna S; Mullen K
Minerva Gastroenterol Dietol; 2014 Mar; 60(1):55-70. PubMed ID: 24632768
[TBL] [Abstract][Full Text] [Related]
17. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis.
Vlachogiannakos J; Viazis N; Vasianopoulou P; Vafiadis I; Karamanolis DG; Ladas SD
J Gastroenterol Hepatol; 2013 Mar; 28(3):450-5. PubMed ID: 23216382
[TBL] [Abstract][Full Text] [Related]
18. Comparison of once a day rifaximin to twice a day dosage in the prevention of recurrence of hepatic encephalopathy in patients with chronic liver disease.
Khokhar N; Qureshi MO; Ahmad S; Ahmad A; Khan HH; Shafqat F; Salih M
J Gastroenterol Hepatol; 2015 Sep; 30(9):1420-2. PubMed ID: 25867912
[TBL] [Abstract][Full Text] [Related]
19. Pharmacotherapy for hepatic encephalopathy.
Phongsamran PV; Kim JW; Cupo Abbott J; Rosenblatt A
Drugs; 2010 Jun; 70(9):1131-48. PubMed ID: 20518580
[TBL] [Abstract][Full Text] [Related]
20. Management of hepatic encephalopathy: role of rifaximin.
Zeneroli ML; Avallone R; Corsi L; Venturini I; Baraldi C; Baraldi M
Chemotherapy; 2005; 51 Suppl 1():90-5. PubMed ID: 15855752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
